Press Releases
October 29, 2010: Orphagen Pharmaceuticals Awarded $622,971 in Qualifying Therapeutic Discovery Project (QTDP) Program Grants.
August 10, 2010: Orphagen Pharmaceuticals Awarded Federal Grant for Adrenocortical and Prostate Cancer.
February 1, 2010: Orphagen is awarded Phase 2 SBIR Funding to Investigate Novel Drug Class for CNS Disorders.
January 7, 2009: Orphagen Pharmaceuticals Announces Collaboration and License Agreement with Japan Tobacco, Inc.
September
1, 2007: National Institutes of Health (NIH) Funds Discovery Research
for Treatment of Rheumatoid Arthritis at Orphagen Pharmaceuticals.
June 1, 2007: Orphagen Pharmaceuticals is Awarded a Phase 1 SBIR Grant for Discovery of Novel Therapeutics for Treatment of MS.
February 16, 2007: Len Post joins the Orphagen Board of Directors.
September 23, 2005: National Institutes of Health awards Orphagen $460,339 to investigate novel treatments for sleep disorders.
May
26, 2005: Orphagen is awarded a Small Business Investigative Research
(SBIR) Phase I grant for drug discovery in the area of metabolic
disease.
